News Releases
Dec 19, 2022
Biodesix Announces First Four Private Payer Coverage Policies for the Nodify XL2® Test
Dec 16, 2022
Biodesix Announces Appointment of Lawrence (Lair) T. Kennedy, Jr. to Board of Directors
Dec 12, 2022
Biodesix Ranked Top Proteomics Solutions Company by Life Sciences Review Magazine
Nov 21, 2022
Biodesix Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares
Nov 17, 2022
Biodesix Announces Pricing of $35.1 Million Upsized Public Offering of Common Stock
Nov 16, 2022
Biodesix Announces Proposed Public Offering of Common Stock
Nov 16, 2022
Biodesix Announces Senior Secured Financing Agreement with Perceptive Advisors for Up to $50 Million
Nov 10, 2022
Biodesix Presents New Data from the INSIGHT Study at the 2022 Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
Nov 03, 2022
Biodesix Announces Third Quarter 2022 Results and Highlights
Oct 20, 2022
Biodesix to Report Third Quarter 2022 Financial Results on November 3, 2022
Displaying 1 - 10 of 39